Drugs / ABX-002
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05528315 | Oct 2022 → Jun 2023 | major depressive disorder | Autobahn Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06869187 | Mar 2025 → Apr 2026 overdue | bipolar depression | Autobahn Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06633016 | Sep 2024 → Jun 2026 overdue | major depressive disorder | Autobahn Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABX-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05528315 ↗ |
| Known as | MA-JD-21 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314909 ↗ |
| Modality | Small molecule | — CHEMBL5314909 ↗ |
| Route | Oral | “ABX-002 oral solution” NCT06633016 ↗ |